

Supplementary Materials

Oral etoposide plus Anlotinib and subcutaneous Envafolimab as a platinum-free, non-intravenous first-line regimen for elderly extensive-stage small cell lung cancer: a phase II trial with biomarker discovery

Man Zhang^{1,#}, Haiyan Sun^{2,#}, Sijia Xing^{2,#}, Yanyang Li^{2,#}, Gang Zhao³, Huiya Wang², Ran Zuo², Shuang Li², Jing Qi², Bin Wang², Zhuchen Yan², Jie Xu⁴, Zhanyu Pan², Zhansheng Jiang²

¹Department of Integrative Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin 300000, China

²Department of Integrative Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.

³Department of Tumor Pathology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.

⁴Department of Lung Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.

[#]These authors contributed equally to this work.

Correspondence to: Prof. Zhansheng Jiang, Zhuchen Yan, Zhanyu Pan, Department of Integrative Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China. E-mail: zhjiang@tmu.edu.cn, yanzc@126.com; Jie Xu, Department of Lung Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China. E-mail: s0010027@163.com; xujie508@126.com

We downloaded public data of 52 SCLC cases and integrated them with data from 15 of our own patients for molecular subtyping. The public SCLC data were obtained from: Nature. 2015 August 6; 524(7563): 47-53. The subtypes included predominantly SCLC-A (10 cases), with two cases each of SCLC-N and SCLC-Y, and one case of SCLC-P.




Figure S1. Molecular subtyping heatmap.




Figure S2. Molecular subtyping of 52 public SCLC cases.